SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
Last trade$0.8423
Day change-$0.0112 (-1.31%)
Day range$0.746 – $0.915
Volume120,896
Market cap$5M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.52M
Price / earnings
—
Price / book
9.63×
Price / sales
2.09×
EV / sales
0.24×
EV / EBITDA
-0.04×
Profitability
Earnings per share
-$2.76
Return on assets
-276.53%
Return on equity
-3,130.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.03×
Quick ratio
1.02×
Cash ratio
0.82×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.22M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ICU, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$635K
$615K
$495K
$420K
$183K
$338K
$293K
$67K
Cost of revenue
$48K
$54K
$46K
$12K
$14K
$27K
$0
$0
Gross profit
$587K
$561K
$449K
$408K
$169K
$311K
$293K
$67K
Selling, general and administrative
$1.59M
$1.83M
$1.71M
$1.22M
$1.9M
$1.03M
$1.68M
$2.1M
Research and development
$3.57M
$2.52M
$2.34M
$2.2M
$1.85M
$1.04M
$2.43M
$2.74M
Total operating expenses
$5.17M
$4.35M
$4.05M
$3.42M
$3.75M
$2.07M
$4.12M
$4.83M
Operating income
-$4.58M
-$3.79M
-$3.6M
-$3.02M
-$3.58M
-$1.76M
-$3.82M
-$4.77M
Interest expense
-$2K
-$8K
-$6K
-$13K
$0
-$9K
-$11K
$253K
Income before taxes
-$4.53M
-$3.73M
-$3.52M
-$2.9M
-$3.47M
-$2M
-$3.77M
-$4.42M
Income taxes
$0
$0
$3K
$0
$0
$0
$3K
$0
Net income
-$4.53M
-$3.73M
-$3.52M
-$2.9M
-$3.47M
-$2M
-$3.77M
-$4.42M
Net income attributable to common shareholders
-$4.53M
-$3.73M
-$3.52M
-$2.9M
-$3.47M
-$2M
-$3.77M
-$4.42M
EBITDA
-$4.58M
-$3.79M
-$3.6M
-$3.02M
-$3.58M
-$1.76M
-$3.82M
-$4.77M
Basic earnings per share
-$1.03
-$0.91
-$0.90
-$0.79
-$1.30
-$1.77
-$4.38
-$8.75
Diluted earnings per share
-$1.03
-$0.91
-$0.90
-$0.79
-$1.30
-$1.77
-$4.38
-$8.75
Recent news
Company coverage with links to the original publishers.
PepGen Inc. experienced a significant 112.4% pre-market stock surge after announcing an underwritten public offering of common stock and pre-funded warrants. Several other stocks showed notable pre-market movements, with some gaining and others declining.
SeaStar Medical announced progress in its NEUTRALIZE-AKI pivotal trial for acute kidney injury treatment, reaching over 60% enrollment with 125 of 200 anticipated patients and 16 clinical trial sites activated.
SeaStar Medical, a commercial-stage healthcare company, announced that it will report its Q1 2025 financial results and host a conference call on May 14, 2025. The company's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA.
SeaStar Medical Holding Corporation, a healthcare company focused on transforming treatments for critically ill patients, announced that it will report its fourth quarter and year-end 2024 financial results on March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.
SeaStar Medical Holding Corporation announced that a 14th site has been activated for its NEUTRALIZE-AKI pivotal trial, which is evaluating the safety and efficacy of its Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI) in intensive care unit patients. The company estimates a significant market opportunity for the SCD in the AKI indication.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.